COL18A1 and neoplasm: Abdollahi and coworkers show that the treatment of tumor xenografts with a combination of endostatin and with VEGF blockers results in an enhanced therapeutic effect, which may be attributed to the endostatin-mediated downregulation of many regulators of proangiogenic pathways and suppression of alternative angiogenic mechanisms that might be upregulated by VEGF blockade [66].